Merck win approval for new diabetes drug

Merck &Co. has won approval from the powerful Food and Drug Administration to sell a novel treatment for type 2 diabetes . The pill, known as Janumet, targets the cause of type 2 and is a combined form of Januvia.
Januvia has been a blockbuster drug for Merck, who are the third biggest maker of prescription drugs in the USA. Janumet combines Januvia and the ubiquitous metformin to create a powerful treatment of type 2 diabetes. Janumet will hit the US diabetes market this month, and may also be approved for distribution in Europe following approval.
The diabetes drug market is enormous, with a number of major companies jostling for the top spot. The fortunes of the big corporation rise and fall, and can be governed by the success or failure of a single drug. Eli Lilly, Merck, Glaxo and others are constantly seeking new drug developments to give them the edge over their competition. It seems that Merck is doing particularly well with its recent diabetes additions.